Amy Garefis sold $16k of ZIP
EVP, Chief People Officer at ZIPRECRUITER, INC.. 2,690 shares at an average of $5.89, traded Mar 18, 2025, filed Mar 18, 2025.
Score components
- +15RoleOfficer
- 0Trade size$16k at market
- 0Share of holdings soldSold 1.3% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -3.8%, 3m -11.0%, 6m -9.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001617553-25-000020, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 15, 2025 | MOption exercise Class A Common Stock10b5-1 | +6,250 | $0.00 | $0 | 204,873 | Mar 18, 2025 |
| Mar 15, 2025 | MOption exercise Class A Common Stock10b5-1 | +5,237 | $0.00 | $0 | 210,110 | Mar 18, 2025 |
| Mar 15, 2025 | MOption exercise Class A Common Stock10b5-1 | +1,337 | $0.00 | $0 | 211,447 | Mar 18, 2025 |
| Mar 15, 2025 | MOption exercise Class A Common Stock10b5-1 | +4,553 | $0.00 | $0 | 216,000 | Mar 18, 2025 |
| Mar 15, 2025 | MOption exercise Class A Common Stock10b5-1 | +5,841 | $0.00 | $0 | 221,841 | Mar 18, 2025 |
| Mar 15, 2025 | FTax withholding Class A Common Stock10b5-1 | -12,324 | $5.96 | $73k | 209,517 | Mar 18, 2025 |
| Mar 18, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -2,690 | $5.89 | $16k | 208,486 | Mar 18, 2025 |
| Mar 15, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -6,250 | $0.00 | $0 | 12,500 | Mar 18, 2025 |
| Mar 15, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -5,237 | $0.00 | $0 | 36,659 | Mar 18, 2025 |
| Mar 15, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -1,337 | $0.00 | $0 | 8,022 | Mar 18, 2025 |
| Mar 15, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -4,553 | $0.00 | $0 | 50,083 | Mar 18, 2025 |
| Mar 15, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -5,841 | $0.00 | $0 | 87,609 | Mar 18, 2025 |
Related signals
Other insiders at ZIPRECRUITER, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | ZIPRECRUITER, INC. | Ian H. Siegel CHIEF EXECUTIVE OFFICER | $103k 29,166 shares | -15% | |
| 10Weak | ZIPRECRUITER, INC. | Ryan T. Sakamoto EVP, Chief Legal Officer | $10k 2,978 shares | -2% | |
| 15Weak | ZIPRECRUITER, INC. | Amy Garefis EVP, Chief People Officer | $30k 7,837 shares | -4% | |
| 37Weak | ZIPRECRUITER, INC. | Ian H. Siegel CHIEF EXECUTIVE OFFICER | $202k 54,422 shares | -21% | |
| 24Weak | ZIPRECRUITER, INC. | David Travers President | $91k 24,705 shares | -2% | |
| 3Weak | ZIPRECRUITER, INC. | Ryan T. Sakamoto EVP, Chief Legal Officer | $13k 2,978 shares | -2% | |
| 9Weak | ZIPRECRUITER, INC. | Amy Garefis EVP, Chief People Officer | $40k 7,819 shares | -4% | |
| 34Weak | ZIPRECRUITER, INC. | Ian H. Siegel CHIEF EXECUTIVE OFFICER | $129k 29,166 shares | -49% | |
| 10Weak | ZIPRECRUITER, INC. | Ryan T. Sakamoto EVP, Chief Legal Officer | $14k 3,547 shares | -3% | |
| 15Weak | ZIPRECRUITER, INC. | Amy Garefis EVP, Chief People Officer | $32k 7,983 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.